The weight-loss drug eloralintide shows up to 20% body weight reduction in trial, offering hope for obesity treatment beyond ...
Remedy Meds is an online consumer health and pharmacy platform that provides access to compounded glucagon-like peptide-one ...
The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...
That said, GLP-1 medications for weight loss are not for everyone, and they can cause unpleasant, even serious, side effects, ...
Eli Lilly said on Friday it plans to roll out an employer-focused obesity care model early next year, aiming to expand access ...
New Scientist on MSN
Daily pill could offer alternative to weight-loss injections
Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...
A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...
Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...
The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...
This article was reviewed by Lynn Marie Morski, MD, JD. Does Ozempic® Lower Blood Pressure? Key Takeaways: Ozempic® may lower ...
Loosely regulated online platforms are promoting powerful obesity shots as a universal weight-loss solution. Photographer: ...
Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback